Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax to Augment Epigenetic Modification and Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE1
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE3
FT576 in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
- Status
- COMPLETED
- Phase
- PHASE4